Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To assess the drug retention rate of interleukin-17 inhibitors (IL-17is) over long-term observation in patients with axial spondyloarthritis (axSpA) in whom treatment with tumor necrosis factor inhibitors (TNFis) failed and to determine baseline fac tors associated with discontinuation of IL-17is. Materials and Methods: This retrospective cohort study included 68 patients with axSpA started on IL-17is after an inadequate re sponse or intolerance to ≥1 TNFis. Drug retention rates at 1, 2, and 3 years were assessed. Baseline (i.e., at initiation of IL-17is) fac tors associated with discontinuation of IL-17is were evaluated using multivariable Cox proportional hazard regression analysis. Results: Over 1933.9 person-months of observation in 68 patients, discontinuation of IL-17is occurred in 27 (39.7%) patients. Twenty (29.4%) patients discontinued IL-17is because of ineffectiveness, and 7 (10.3%) patients discontinued IL-17is because of adverse events. The 1-year, 2-year, and 3-year drug retention rates for IL-17is were 71.9%, 66.5%, and 62.0%, respectively. Current smoking was associated with a higher risk of IL-17is discontinuation [adjusted hazard ratio (HR)=2.256, 95% confidence interval (CI)=1.053–4.831, p=0.036], while previous use of ≥3 TNFis (vs. 1) was significantly associated with a lower risk of IL-17is discon tinuation (adjusted HR=0.223, 95% CI=0.051–0.969, p=0.045). Conclusion: In patients with axSpA in whom TNFis failed, the long-term drug retention rate of IL-17is appears to be acceptable, with a 3-year drug retention rate of approximately 60%. Current smoking was associated with a higher risk of discontinuing IL 17is, whereas previous use of ≥3 TNFis was associated with a lower risk of discontinuing IL-17is.
Abstract
Purpose: To assess the drug retention rate of interleukin-17 inhibitors (IL-17is) over long-term observation in patients with axial spondyloarthritis (axSpA) in whom treatment with tumor necrosis factor inhibitors (TNFis) failed and to determine baseline fac tors associated with discontinuation of IL-17is. Materials and Methods: This retrospective cohort study included 68 patients with axSpA started on IL-17is after an inadequate re sponse or intolerance to ≥1 TNFis. Drug retention rates at 1, 2, and 3 years were assessed. Baseline (i.e., at initiation of IL-17is) fac tors associated with discontinuation of IL-17is were evaluated using multivariable Cox proportional hazard regression analysis. Results: Over 1933.9 person-months of observation in 68 patients, discontinuation of IL-17is occurred in 27 (39.7%) patients. Twenty (29.4%) patients discontinued IL-17is because of ineffectiveness, and 7 (10.3%) patients discontinued IL-17is because of adverse events. The 1-year, 2-year, and 3-year drug retention rates for IL-17is were 71.9%, 66.5%, and 62.0%, respectively. Current smoking was associated with a higher risk of IL-17is discontinuation [adjusted hazard ratio (HR)=2.256, 95% confidence interval (CI)=1.053–4.831, p=0.036], while previous use of ≥3 TNFis (vs. 1) was significantly associated with a lower risk of IL-17is discon tinuation (adjusted HR=0.223, 95% CI=0.051–0.969, p=0.045). Conclusion: In patients with axSpA in whom TNFis failed, the long-term drug retention rate of IL-17is appears to be acceptable, with a 3-year drug retention rate of approximately 60%. Current smoking was associated with a higher risk of discontinuing IL 17is, whereas previous use of ≥3 TNFis was associated with a lower risk of discontinuing IL-17is.
참고문헌 (31)
- van der Heijde D, "Efficacy and safety of infliximab in patients with ankylosing spondylitis : results of a randomized, placebocontrolled trial(ASSERT)", Arthritis Rheum, 52, pp.582~591 (2005)
- Davis JC Jr, "Recombinant human tumor necrosis factor receptor(etanercept)for treating ankylosing spondylitis : a randomized, controlled trial", Arthritis Rheum, 48, pp.3230~3236 (2003)
- van der Heijde D, "Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 54, pp.2136~2146 (2006)
- Inman RD, "Efficacy and safety of golimumab in patients with ankylosing spondylitis : results of a randomized, double-blind, placebo-controlled, phase III trial", Arthritis Rheum, 58, pp.3402~3412 (2008)
- Landewé R, "Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis : 24-week results of a double-blind randomised placebocontrolled phase 3 study", Ann Rheum Dis, 73, pp.39~47 (2014)
- Ward MM, "2019 update of the American College of Rheumatology", Spondylitis Association of America, Arthritis Rheumatol, pp.2019, 71[DOI]
- Ramiro S, "ASAS-EULAR recommendations for the management of axial spondyloarthritis : 2022 update", Ann Rheum Dis, 82, pp.19~34 (2023)
- Navarro-Compán V, "Axial spondyloarthritis", Ann Rheum Dis, 80, pp.1511~1521 (2021)
- Kwon OC, "Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor", Ther Adv Musculoskelet Dis, 13 (2021)
- Fraenkel L, "2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 73, pp.1108~1123 (2021)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2022 update", Ann Rheum Dis, 82, pp.3~18 (2023)
- Gossec L, "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019update", Ann Rheum Dis, 79, pp.700~712 (2020)
- Glintborg B, "Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with antitumour necrosis factor : results from 8 years’ surveillance in the Danish nationwide DANBIO registry", Ann Rheum Dis, 69, pp.2002~2008 (2010)
- Lie E, "Effectiveness of switching between TNF inhibitors in ankylosing spondylitis : data from the NOR-DMARD register", Ann Rheum Dis, 70, pp.157~163 (2011)
- Kim HA, "Comparison of retention rates between tumor necrosis factor-α inhibitors in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics Registry", Front Med(Lausanne), 8, pp.689609~ (2021)
- Michelsen B, "Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration", RMD Open, 6, pp.e001280~ (2020)
- Alonso S, "Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in cantabria and ASTURias study", Front Med(Lausanne), 8, pp.679009~ (2021)
- Moreno-Ramos MJ, "Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis : a descriptive observational analysis of the Spanish BIOBADASER registry", Rheumatol Ther, 9, pp.1031~1047 (2022)
- Armag˘an B, "Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis", Rheumatol Int, 43, pp.147~156 (2023)
- Min HK, "Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure", Rheumatology(Oxford), 60, pp.5743~5752 (2021)
- Rudwaleit M, "The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis(part II) : validation and final selection", Ann Rheum Dis, 68, pp.777~783 (2009)
- van der Linden S, "Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria", Arthritis Rheum, 27, pp.361~368 (1984)
- Garrett S, "A new approach to defining disease status in ankylosing spondylitis : the bath ankylosing spondylitis disease activity index", J Rheumatol, 21, pp.2286~2291 (1994)
- Lukas C, "Development of an ASAS-endorsed disease activity score(ASDAS)in patients with ankylosing spondylitis", Ann Rheum Dis, 68, pp.18~24 (2009)
- 김진현, "KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities", 대한류마티스학회지, 28(4), pp.176~182 (2021), 대한류마티스학회
- Chimenti MS, "One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis : a real-life multicenter study", Expert Opin Biol Ther, 20, pp.813~821 (2020)
- Zhao S, "Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis", Rheumatol Int, 37, pp.239~244 (2017)
- Zhang H, "Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis", Clin Rheumatol, 37, pp.1605~1616 (2018)
- Poddubnyy D, "Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis", Arthritis Rheum, 64, pp.1388~1398 (2012)
- Queiro R, "Obesity in psoriatic arthritis : comparative prevalence and associated factors", Medicine(Baltimore), 98, pp.e16400~ (2019)
- Pantano I, "Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index", Ann Rheum Dis, 81, pp.e42~ (2022)